![Sage Therapeutics Discontinues Parkinson's Drug Following Mid-Stage Trial Failure](/content/images/size/w600/2024/04/e7ffe258-68c9-4192-a190-38c6b3a2f5f8.png)
Business
Sage Therapeutics Discontinues Parkinson's Drug Following Mid-Stage Trial Failure
Sage Therapeutics has announced the discontinuation of its experimental drug, dalzanemdor, intended for the treatment of Parkinson's disease, after it failed to meet the primary goal in a mid-stage study. The drug, also known as SAGE-718, did not demonstrate a statistically significant difference in the Wechsler Adult Intelligence